Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)

---

Copy For Citation

EKİCİ B., Yaman M., KÜÇÜK M., Dereli S., Yenercag M., Yigit Z., ...More

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.49, no.5, pp.357-368, 2021 (ESCI)

• Publication Type: Article / Article
• Volume: 49 Issue: 5
• Publication Date: 2021
• Doi Number: 10.5543/tkda.2021.63099
• Journal Name: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
• Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
• Page Numbers: pp.357-368
• Recep Tayyip Erdoğan University Affiliated: Yes

Abstract

Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.